SCHEMBL2955820

SCHEMBL2955820

COc1cccc(CO)c1Cc1c(C(=O)OC(C)(C)C)c(OC)cc2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC37A4 O43826 6/20 0.46
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
PDCD1 Q15116 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
ELANE P08246 2/20 0.35
HSP90AA1 P07900 1/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
MAPT P10636 3/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
DUSP3 P51452 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ITGA4 P13612 1/20 0.34
ITGB7 P26010 1/20 0.34
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947006 0.86 SLC37A4 (0.48) SLC37A4MTNR1AMTNR1BELANEMEN1
SCHEMBL4463509 0.85 MTNR1A (0.40) SLC37A4MTNR1AMTNR1BPDCD1CD274
SCHEMBL2955955 0.81 SLC37A4 (0.45) SLC37A4MTNR1AMTNR1BMEN1KMT2A
Anthraquinone SCHEMBL2946623 0.81 SLC37A4 (0.45) SLC37A4MTNR1AMTNR1BMEN1KMT2A
SCHEMBL2948794 0.81 SLC37A4 (0.44) SLC37A4MTNR1AMTNR1BKMT2AALDH1A1
Anthraquinone SCHEMBL2948902 0.79 SLC37A4 (0.48) SLC37A4ELANEMEN1KMT2A
SCHEMBL2946624 0.77 SLC37A4 (0.48) SLC37A4ELANEMEN1KMT2A
SCHEMBL2957671 0.77 MAPT (0.44) SLC37A4MEN1KMT2AMAPTRAB9A
SCHEMBL2959701 0.76 SLC37A4 (0.38) SLC37A4
SCHEMBL2956199 0.75 SLC37A4 (0.36) SLC37A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763740-B2 Method for the production of mumbaistatin derivatives SANOFI-AVENTIS (FR) 2010-07-27 US disclosed
US-20090156836-A1 METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES SANOFI-AVENTIS (FR) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156836-A1 METHOD FOR THE PRODUCTION OF MUMBAISTATIN DERIVATIVES MMAB, MLYCD, HMBS SLC37A4 4052/4885MTNR1A 2389/4885MTNR1B 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.